A via L-arginina-óxido nítrico em plaquetas de adolescente com obesidade e síndrome metabólica

• Autor(a) principal: Assumpção, Carmen Regina Leal de
• Data de Publicação: 2010
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/12596
• topic: Obesity; Metabolic Syndrome; Platelet; Nitric oxide; L-arginine; System y+L; Obesidade; Síndrome Metabólica; Plaqueta; Óxido nítrico; L-arginina; Sistema y+L.; CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA::FARMACOLOGIA CARDIORENAL

The prevalence of obesity and metabolic syndrome (MS) is dramatically increasing in young people and becoming a public health problem in the majority of developed and developing countries. Both obesity and MS increase the number of patients exposed to the risk of cardiovascular disease. Recent studies have shown that a reduction in nitric oxide (NO) bioavailability is one of the major factors contributing to the deleterious action of insulin in the blood vessels of adult patients with obesity and MS. NO, a powerful vasodilator and platelet anti-aggregating agent, has the cationic amino acid L-arginine as a precursor, which is transported into platelets via transport system y+L. A family of enzymes known as NO sinthases (NOS) catalyses the oxidation of L-arginine in NO and L-citrulline and is composed of three isoforms: neuronal (nNOS), inducible (iNOS) and endothelial (eNOS). The major objectives of this study are to investigate different steps of the L-arginine-NO pathway in platelets and their association with platelet aggregation, L-arginine plasma concentration, oxidative stress, and metabolic, hormonal, clinical and inflammatory markers in adolescent patients with obesity and MS. Thirty adolescents were included in this study: ten with obesity, ten with MS and ten healthy controls paired by age, sex and Tanner classification (controls: n= 10, 15.6 ± 0.7 years; obese: n= 10, 15 ± 0.9 years; MS: n= 10, 14.9 ± 0.8 years). Larginine transport (pmol/109cells/min) via system y+L was reduced in patients with MS (18.4 ± 3.8) and obesity (20.8 ± 4.7) compared to controls (52.3 ± 14.8). There was a positive correlation between L-arginine influx via system y+L and HDL-cholesterol. On the other hand, a negative correlation was found between L-arginine influx via system y+L and insulin levels, Homa-IR related to insulin resistance, Homa-Beta, related to betacell function and the leptin index. In relation to nitric oxide production, obesity and MS do not affect the activity and expression of NOS enzymes. The activity of superoxide dismutase (SOD), by measuring the inhibition of adrenaline autoxidation, showed a significant difference in platelets from patients with obesity (4235 ± 613,2nMol/mg protein) compared to controls (1011± 123,6 nmol/mg de protein) and MS (1713 ± 267,7 nmol/mg protein). At the systemic level, an activation of this anti-oxidant enzyme was also observed in the serum of patients with obesity and MS in relation to controls in the presence of similar levels of substances that are reactive to tiobarbituric acid (TBARS), a marker of lipid peroxidation. These results suggest that diminished L-arginine transport in platelets from adolescents with obesity and MS may be an early marker of platelet dysfunction. The alteration of this pathway correlates to insulin resistance and hyperinsulinemia. The contribution of this study and of factors that can be identified early may reduce cardiovascular risk during adult life in this population of patients.